Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Healthcare Triangle, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
31.3
35.3
45.9
33.2
11.7
13.9
Cost of revenue
22.8
24.7
34.6
26.4
8.81
12
Gross profit
8.59
10.5
11.3
1,070
1,070
1,235
Research and development
1.74
5.26
8.14
0.8
0.43
0.54
Selling, general and administrative
0
0
Selling and marketing
2.42
4.76
6.65
4.67
2.2
3.08
General and administrative
2.44
4.44
5.52
5.73
3.95
7.34
Operating expenses
15.9
27.6
14.5
7.64
11.7
Operating income
1.18
-5.36
-16.3
-7.7
-4.75
-9.79
Interest expense
0.08
0.57
0.21
0.97
0.57
Other non-operating income
1.43
-0.57
Pre-tax income
2.61
-5.93
-13.9
-8.65
-5.96
-9.48
Income tax
0.26
0.02
0.51
0.04
0.01
Income from continuing operations
2.69
-5.36
-10.4
4.75
9.79
Net income to minority interests
-0.04
Net income
2.35
-5.95
-14.4
-8.69
-5.97
-9.48
EBITDA
1.98
-3.94
-13.4
-6.13
-3.86
-9.08
EPS, basic
1,257.00
-3,023.00
-58,060.00
-31,125.00
-16,909.00
-152.30
EPS, diluted
1,257.00
-3,023.00
-58,060.00
-31,125.00
-16,909.00
-152.30
Shares, basic (weighted)
0
0
0
0
0
0.06
Shares, diluted (weighted)
0
0
0
0
0
0.06
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
1.4
1.77
1.34
1.23
0.02
7.63
Receivables
6.4
9.67
5.87
3.6
1.11
2.07
Other current assets
0.23
0.36
0.82
0.82
0.32
3.46
Total current assets
8.03
11.8
8.02
5.65
1.45
13.2
Property, plant and equipment
0.02
0.07
0.08
0.04
0.01
0.01
Lease right-of-use assets
0.17
Goodwill
1.29
1.29
2.95
Intangible assets
2.62
10.5
4.09
0.86
2.81
Total assets
11.1
24.6
13.3
6.86
1.96
22.7
Accounts payable
4.35
1.87
1.48
1.95
2.54
0.74
Short-term debt
2.21
2.69
3.79
2.65
10.7
Total current liabilities
6.78
6.25
6.6
8.15
7.08
12.8
Long-term debt
0.1
10.5
Total liabilities
6.78
8.48
7.22
8.25
7.08
12.8
Total debt
0.89
Paid-in capital
1.04
18.8
25
26.2
21
45.5
Retained earnings
-2.66
-18.9
-27.6
-33.6
-43
Shareholders' equity
4.33
14.2
6.04
0.54
-5.11
Minority interests
-0.04
Total equity
4.33
16.1
12.4
-1.39
-5.11
9.94
Total liabilities and equity
11.1
24.6
13.3
6.86
1.96
22.7
Shares outstanding
0
0
0
0
0
0.14
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
2.35
-5.95
-1.39
-0.4
-5.97
-9.48
Depreciation and amortization
0.8
1.42
2.94
1.57
0.89
0.71
Stock-based compensation
0.05
0.26
0.17
0.09
0.45
Change in receivables
-2.23
-3.28
3.59
2.27
2.32
-0.91
Change in payables
-0.75
-2.48
-0.39
0.48
0.59
-1.49
Cash from operations
-0.73
-7.11
-5.35
-2.15
-1.08
-16.5
Capital expenditures
-0.04
-0.01
-0.01
Cash from investing
-0.48
-7.63
-1.13
-0.01
-1.75
Stock issued
14.2
5.89
0.5
9.83
Share buybacks
-0.14
Cash from financing
1.64
15.1
6.06
2.06
-0.13
25.9
Net change in cash
0.43
0.37
-0.43
-0.11
-1.21
7.61
Free cash flow
-5.39
-2.16
-16.5
Interest paid
0.21
0.97
0.12
0.57
Income taxes paid
0.26
0.02
0.06
0.04
0.01
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.78 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
4,824.0%
Gross profit / revenue.
Operating margin
-57.4%
Operating income / revenue.
EBITDA margin
-49.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-66.2%
Pre-tax income / revenue.
Net margin
-66.3%
Net income / revenue.
Operating cash flow margin
-62.4%
Cash from operations / revenue.
Return on assets (ROA)
-23.1%
Net income / average total assets.
R&D / revenue
1.8%
Research and development expense / revenue.
D&A / revenue
7.9%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
18.8%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-32.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-15.0%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
15.4%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
378.2%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
170.1%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
1,059.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
19.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
15.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
17,428.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
530.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
101.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.60x
Current assets / current liabilities.
Quick ratio
0.51x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.12x
(Cash + short-term investments) / current liabilities.
Debt / assets
11.0%
Total debt / total assets.
Liabilities / assets
33.3%
Total liabilities / total assets.
Net debt
$6.2M
Total debt - cash - short-term investments. Negative means more cash than debt.
Working capital
-$6.3M
Current assets - current liabilities.
Goodwill and intangibles / assets
10.4%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.35x
Revenue / average total assets.
Fixed asset turnover
21.5x
Revenue / average property, plant and equipment.
Receivables turnover
4.15x
Revenue / average receivables.
Days sales outstanding
88 days
365 x average receivables / revenue.
Days payables
22 days
365 x average accounts payable / cost of revenue.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$6.07
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Market cap + total debt - cash - short-term investments.
P/S
0.45x
Market cap / revenue.
EV/Sales
0.70x
Enterprise value / revenue.
Earnings yield
-146.1%
Net income / market cap (the inverse of P/E).
What was Healthcare Triangle, Inc.'s revenue in fiscal 2025?
Healthcare Triangle, Inc. reported revenue of $13.9M for fiscal 2025, 18.8% higher than the year before.
Was Healthcare Triangle, Inc. profitable in fiscal 2025?
No. It reported a net loss of $9.5M.
How much free cash flow did Healthcare Triangle, Inc. generate in fiscal 2025?
Cash from operations of $16.5M minus capital expenditures of $6.0K left free cash flow of -$16.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.